DaShenLin Pharmaceutical - Public Comps and Valuation Multiples

DaShenLin Pharmaceutical Overview

About DaShenLin Pharmaceutical

DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.

Founded

1999

HQ

Employees

n/a

Website

dslyy.com

Sectors

Pharmacies

Financials

LTM Revenue $3.9B

LTM EBITDA $448M

EV

$2.9B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

DaShenLin Pharmaceutical Financials

As of September 2025, DaShenLin Pharmaceutical reported last 12-month revenue of $3.9B and EBITDA of $448M.

In the same period, DaShenLin Pharmaceutical generated $1.3B in LTM gross profit and $157M in net income.

See DaShenLin Pharmaceutical valuation multiples based on analyst estimates

DaShenLin Pharmaceutical P&L

In the most recent fiscal year, DaShenLin Pharmaceutical reported revenue of $3.7B and EBITDA of $425M.

DaShenLin Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See DaShenLin Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$3.9B	XXX	$3.7B	XXX	XXX	XXX
Gross Profit	$1.3B	XXX	$1.3B	XXX	XXX	XXX
Gross Margin	34%	XXX	34%	XXX	XXX	XXX
EBITDA	$448M	XXX	$425M	XXX	XXX	XXX
EBITDA Margin	11%	XXX	11%	XXX	XXX	XXX
EBIT	$237M	XXX	$226M	XXX	XXX	XXX
EBIT Margin	6%	XXX	6%	XXX	XXX	XXX
Net Profit	$157M	XXX	$128M	XXX	XXX	XXX
Net Margin	4%	XXX	3%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for DaShenLin Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $3.9B. EBITDA for the last twelve months was $448M. In the most recent fiscal year, DaShenLin Pharmaceutical achieved $3.7B in revenue and $425M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$3.9B	Analyst estimates available to subscribers	$3.7B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.3B	Analyst estimates available to subscribers	$1.3B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	34.4% gross margin	Analyst estimates available to subscribers	34.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$448M	Analyst estimates available to subscribers	$425M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	11.5% EBITDA margin	Analyst estimates available to subscribers	11.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$237M	Analyst estimates available to subscribers	$226M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	6.1% EBIT margin	Analyst estimates available to subscribers	6.1% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$157M	Analyst estimates available to subscribers	$128M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	4.0% net profit margin	Analyst estimates available to subscribers	3.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for DaShenLin Pharmaceutical

This financial data table provides comprehensive performance metrics for DaShenLin Pharmaceutical, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

DaShenLin Pharmaceutical generated $3.9B in revenue over the last twelve months.
The company achieved $448M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.3B.
Net income over the last twelve months reached $157M.

Fiscal Year Performance

In the most recent fiscal year, DaShenLin Pharmaceutical reported $3.7B in total revenue.
Fiscal year EBITDA was $425M.
The company maintained a gross profit margin of 34.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 11.4%.
Net profit margin reached 3.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for DaShenLin Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

DaShenLin Pharmaceutical Stock Performance

DaShenLin Pharmaceutical has current market cap of CNY 20.7B (or $2.9B), and EV of CNY 20.7B (or $2.9B).

Market Cap Evolution

DaShenLin Pharmaceutical Stock Data

As of October 30, 2025, DaShenLin Pharmaceutical's stock price is CNY 18 (or $3).

See DaShenLin Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.9B	$2.9B	XXX	XXX	XXX	XXX	$0.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

DaShenLin Pharmaceutical Valuation Multiples

DaShenLin Pharmaceutical's trades at 0.8x EV/Revenue multiple, and 6.9x EV/EBITDA.

See valuation multiples for DaShenLin Pharmaceutical and 15K+ public comps

DaShenLin Pharmaceutical Financial Valuation Multiples

As of October 30, 2025, DaShenLin Pharmaceutical has market cap of $2.9B and EV of $2.9B.

Equity research analysts estimate DaShenLin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

DaShenLin Pharmaceutical has a P/E ratio of 18.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.9B	XXX	$2.9B	XXX	XXX	XXX
EV (current)	$2.9B	XXX	$2.9B	XXX	XXX	XXX
EV/Revenue	0.7x	XXX	0.8x	XXX	XXX	XXX
EV/EBITDA	6.5x	XXX	6.9x	XXX	XXX	XXX
EV/EBIT	12.3x	XXX	12.9x	XXX	XXX	XXX
EV/Gross Profit	2.2x	XXX	n/a	XXX	XXX	XXX
P/E	18.5x	XXX	22.6x	XXX	XXX	XXX
EV/FCF	13.2x	XXX	12.7x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get DaShenLin Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

DaShenLin Pharmaceutical Margins & Growth Rates

DaShenLin Pharmaceutical's last 12 month revenue growth is 10%

DaShenLin Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

DaShenLin Pharmaceutical's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

DaShenLin Pharmaceutical's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for DaShenLin Pharmaceutical and other 15K+ public comps

DaShenLin Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	10%	XXX	8%	XXX	XXX	XXX
EBITDA Margin	11%	XXX	11%	XXX	XXX	XXX
EBITDA Growth	11%	XXX	1%	XXX	XXX	XXX
Rule of 40	23%	XXX	21%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	36%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	28%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial